Rokit Healthcare
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Rokit Healthcare develops regenerative-medicine treatments, therapies that aim to repair or regrow damaged tissue, targeting conditions such as diabetic foot ulcers, chronic wounds, cartilage damage from osteoarthritis, and chronic kidney disease.
Its products are intended for use in clinical and hospital settings, addressing patients where standard treatments such as dressings, injections, or dialysis fall short. Listed on KOSDAQ, South Korea's tech-focused small-cap exchange, the company's platform is built around bioprinting and tissue-engineering technology applied across multiple therapeutic areas rather than a single product line.
Summary is AI-generated and may contain errors · figures from DART filings
Rokit Healthcare in five facts
What does Rokit Healthcare do?
Rokit Healthcare develops regenerative-medicine treatments, therapies that aim to repair or regrow damaged tissue, targeting conditions such as diabetic foot ulcers, chronic wounds, cartilage damage from osteoarthritis, and chronic kidney disease.
Where is Rokit Healthcare listed and in which sector?
Rokit Healthcare (Korean name: 로킷헬스케어) trades under KRX code 376900 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Rokit Healthcare?
Its market capitalisation was US$295.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Rokit Healthcare's latest annual revenue and operating profit?
For fiscal year 2025, Rokit Healthcare reported revenue of US$19.8M, operating profit of US$341.8K and a net loss of US$2.1M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 100.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- DisclosureOct 19
- [Amended] Half-year report (2026.06)Oct 1
- Material event report (rights offering)
Rokit Healthcare disclosed convertible bonds to raise US$42.7M, about 12.6% of its market value.
Capital raise · Mar 10 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Rokit Healthcare reported consolidated results for FY2025: revenue of US$18M (+100.2% year on year), operating profit of US$417K (from a loss a year earlier) and a net loss of US$1.57M.
Earnings · Feb 11